<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present study, neuroprotective effect of 4-amino-1,8-napthalimide (4-ANI), a poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase (PARP) inhibitor was investigated in middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo)-induced focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Sprague-Dawley rats were subjected to 2 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 22 h of reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>After 22 h of reperfusion rats were evaluated for <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, neurological deficits, brain <z:chebi fb="0" ids="13389">NAD</z:chebi> levels, and in situ terminal deoxynucleotidyl transferase mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi>-<z:chebi fb="1" ids="15956">biotin</z:chebi> nick end labeling (TUNEL) </plain></SENT>
<SENT sid="3" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> produced significant <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (201 +/- 14 mm3), neurological scores (2 +/- 0.5) and 28 +/- 4.5% brain <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was associated with increased in TUNEL positive cells in brain sections indicating DNA fragmentation </plain></SENT>
<SENT sid="5" pm="."><plain>4-ANI treatment (1 and 3 mg/kg, i.p.) significantly decreased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to 35 +/- 7% and 70 +/- 6%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Neurological functions were also significantly improved at these doses </plain></SENT>
<SENT sid="7" pm="."><plain>4-ANI (3 mg/kg) completely reversed brain <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> and significantly reduced the increase in the number of TUNEL positive cells </plain></SENT>
<SENT sid="8" pm="."><plain>Nevertheless, 4-ANI treatment did not alter cerebral blood flow and blood pressure </plain></SENT>
<SENT sid="9" pm="."><plain>Our study suggests 4-ANI is a potent neuroprotective agent in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and its neuroprotective effects may be attributed to reduction of <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> and DNA fragmentation </plain></SENT>
</text></document>